OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
OncClub: Join the Chat on Trending Trials in CancerComplimentary print subscription for home or office deliveryIn-person and virtual events just for HCPsLively expert panel discussions featuring peer-to-peer exchangesSubscribe to our eNewsletter for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • OncClub: Join the Chat on Trending Trials in Cancer
  • Complimentary print subscription for home or office delivery
  • In-person and virtual events just for HCPs
  • Lively expert panel discussions featuring peer-to-peer exchanges
  • Subscribe to our eNewsletter for breaking news and curated content
SpecialtySee All >
  • Breast Cancer
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Amanda Nickles Fader, MD

  1. home

Articles

Dr. Fader on Trastuzumab/Chemo in HER2+ Uterine Serous Carcinoma

April 24th 2020

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Dr. Fader on the Rationale for Targeting HER2/neu in Uterine Serous Carcinoma

April 15th 2020

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Dr. Fader on Adding Trastuzumab to Chemo in HER2+ Uterine Serous Carcinoma

April 9th 2020

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.